GRANIX
Peaktbo-filgrastim
BLAINJECTIONINJECTABLE
Approved
Aug 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
GRANIX (tbo-filgrastim) is tbo-filgrastim is a human granulocyte colony-stimulating factor (g-csf) produced by recombinant dna technology. First approved in 2012.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GRANIX (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) approved in 2012 for chemotherapy-induced neutropenia. It binds to G-CSF receptors to stimulate neutrophil proliferation and differentiation, restoring immune function in cancer patients undergoing myelosuppressive chemotherapy.
$0.002BPart D
PeakProduct is at peak lifecycle with modest Part D spending ($2M) and stable market presence, suggesting mature team with focus on retention and efficiency rather than aggressive expansion.
Mechanism of Action
Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which…
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Started May 2015
50 enrolled
Neutropenia
Career Relevance
GRANIX represents a mature specialty biologic with established market position but limited growth trajectory, making it suitable for professionals seeking stable, focused roles in oncology and hematology specialty segments. Career progression typically leads to larger franchise portfolios, more competitive indications, or transition to emerging pipeline assets.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.